Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index; 13 of the 27 sources its claims cite were checked for support.

NRK1 controls nicotinamide mononucleotide and nicotinamide riboside metabolism in mammalian cells

Open access

Abstract

Here we show that nicotinamide riboside kinase 1 (NRK1) is necessary and rate-limiting for the use of exogenous NR and NMN for NAD+ synthesis. Using stable isotope-labelled compounds, we confirm NMN is metabolized extracellularly to NR that is then taken up by the cell and converted into NAD+.

Overview

CoChat Summary

## TL;DR

NRK1 is the key rate-limiting enzyme that mammalian cells and liver require to convert exogenous nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) into NAD+. The paper shows that NMN is first dephosphorylated extracellularly to NR, which is then taken up and used for NAD+ synthesis.

## Key findings

  • In NIH/3T3 cells, overexpression of active NRK1 or NRK2 converted NR-nonresponsive cells into NR-responsive cells, producing about a 4-fold increase in NAD+; catalytically inactive NRK1-D36A and NRK2-D35A did not.
  • In F3T3-NRK1 cells, NR increased NAD+ at concentrations as low as 100 μM, with maximal effects at about 1 mM; NMN increased NAD+ only in NRK1-overexpressing cells and less potently than NR, while NAM worked regardless of NRK1.
  • In primary hepatocytes from NRK1KO mice, NR and NMN failed to increase NAD+, whereas NA and NAM still increased NAD+ normally.
  • In vivo, 500 mg kg−1 intraperitoneal NR raised liver NAD+ by about 220% in wild-type mice; NMN and NAM raised it by about 170%, and NR/NMN responses were significantly blunted in NRK1KO mice, though about 60% of the NR and NMN effect remained.

## Methods

  • The study used gain- and loss-of-function models: transient and stable NRK1/NRK2 overexpression in cell lines, siRNA knockdown of Nmrk1 in AML12 hepatocytes, and a constitutive Nmrk1 knockout mouse.
  • NAD+ precursor metabolism was tested in cultured cells, primary hepatocytes, primary brown adipocytes, and mice using NR, NMN, NAM, and NA treatments, plus isotope-labeled compounds for flux analysis.
  • Main analyses included NAD+ quantification by assay, targeted LC-MS/LC-QqQ MS metabolomics, western blotting, and qPCR; statistical testing used t-tests or one-way ANOVA with Bonferroni post-test.

## Limitations

  • The paper states that data are available only upon request, which limits immediate reproducibility access.
  • The text makes evident that several mechanistic claims rely on high-dose precursor injections in mice (e.g., 500 mg kg−1 and 50 mg kg−1), so some in vivo effects may not reflect physiological exposure; this is evident from the text.
  • The paper itself notes that future work is needed to better characterize circulating NAD+, NMN, and NR and to optimize organ-targeted formulations.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/ncomms13103

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 NRKs are rate-limiting for NR-driven NAD+ synthesis. (a,b) NIH/3T3 cells were transfected with 4 μg of Flag-tagged WT and catalytically inactive version of NRK1 or NRK2 overexpressing vector. Nmrk1 and Nmrk2 mRNA (a) and NRK1/NRK2 protein (b) expression. (c) NAD+ measurement in NR-treated NIH/3T3 cells overexpressing NRK1 or NRK2. Results shown are mean±s.e.m.; EV, empty vector; *P<0.05 versus ctrl by two-sided unpaired T-test (n=3).
Figure 1 NRKs are rate-limiting for NR-driven NAD+ synthesis. (a,b) NIH/3T3 cells were transfected with 4 μg of Flag-tagged WT and catalytically inactive version of NRK1 or NRK2 overexpressing vector. Nmrk1 and Nmrk2 mRNA (a) and NRK1/NRK2 protein (b) expression. (c) NAD+ measurement in NR-treated NIH/3T3 cells overexpressing NRK1 or NRK2. Results shown are mean±s.e.m.; EV, empty vector; *P<0.05 versus ctrl by two-sided unpaired T-test (n=3).CC BY · PubMed Central
Figure 2 Slight overexpression of NRKs potentiates NR- and NMN-driven NAD+ synthesis. (a) NRK1 and NRK2 protein expression and mRNA levels in NIH/3T3 and stable cell lines with one additional copy of either of NRK (F3T3 cells). (b) NAD+ measurement in NR dose-response treatment of F3T3 cells. (c) Schematic of NAD+ precursors metabolism (d–f) NAD+ measurement in F3T3 cells treated for 6 h with 0.5 mM NR (d), 0.5 mM NMN (e) and 5.0 mM NAM (f). Results shown are mean±s.e.m., *P<0.05, **P<0.01, ***P<0.001 versus ctrl by two-sided unpaired T-test (n=3).
Figure 2 Slight overexpression of NRKs potentiates NR- and NMN-driven NAD+ synthesis. (a) NRK1 and NRK2 protein expression and mRNA levels in NIH/3T3 and stable cell lines with one additional copy of either of NRK (F3T3 cells). (b) NAD+ measurement in NR dose-response treatment of F3T3 cells. (c) Schematic of NAD+ precursors metabolism (d–f) NAD+ measurement in F3T3 cells treated for 6 h with 0.5 mM NR (d), 0.5 mM NMN (e) and 5.0 mM NAM (f). Results shown are mean±s.e.m., *P<0.05, **P<0.01, ***P<0.001 versus ctrl by two-sided unpaired T-test (n=3).CC BY · PubMed Central
Figure 3 NRK1 and NR metabolism in hepatic cells. (a) Protein levels of NRK1 in mouse tissues. (b) 7–9 weeks old WT male mice were IP injected with 500 mg kg−1 of NR or vehicle and tissues were collected after 1 h. NAD+ measurement in selected tissues, n=5 per group. (c,d) AML12 (c) and HepG2 (d) cells were transfected with NRK1-overexpressing vector. NRK1 protein levels and NAD+ measurement after 6 h 0.5 mM NR treatment. Results shown are mean±s.e.m., *P<0.05, **P<0.01, ***P<0.001 versus ctrl; #P<0.05 versus EV by two-sided unpaired T-test or (in c and d) one-way ANOVA followed by Bonferroni's post-hoc test (n=3).
Figure 3 NRK1 and NR metabolism in hepatic cells. (a) Protein levels of NRK1 in mouse tissues. (b) 7–9 weeks old WT male mice were IP injected with 500 mg kg−1 of NR or vehicle and tissues were collected after 1 h. NAD+ measurement in selected tissues, n=5 per group. (c,d) AML12 (c) and HepG2 (d) cells were transfected with NRK1-overexpressing vector. NRK1 protein levels and NAD+ measurement after 6 h 0.5 mM NR treatment. Results shown are mean±s.e.m., *P<0.05, **P<0.01, ***P<0.001 versus ctrl; #P<0.05 versus EV by two-sided unpaired T-test or (in c and d) one-way ANOVA followed by Bonferroni's post-hoc test (n=3).CC BY · PubMed Central
Figure 4 Extracellular NMN dephosphorylates to NR. HepG2 cells were treated with [18O]-labelled NR (a,b) or NMN (c,d). Intracellular enrichment of labelled compounds (a,c) and presence of labelled compounds in the media of treated cells (b,d). Results shown are mean±s.e.m. (n=3).
Figure 4 Extracellular NMN dephosphorylates to NR. HepG2 cells were treated with [18O]-labelled NR (a,b) or NMN (c,d). Intracellular enrichment of labelled compounds (a,c) and presence of labelled compounds in the media of treated cells (b,d). Results shown are mean±s.e.m. (n=3).CC BY · PubMed Central
Figure 5 NRK1 is essential for NR and NMN to enhance NAD+ synthesis in hepatic cells. (a,b) AML12 cells were transfected with NRK1 siRNA. (a) Protein and mRNA levels of NRK1 and other NAD+-related enzymes. (b) NAD+ measurement after 6 h 0.5 mM NR treatment. *P<0.05 versus ctrl by two-sided unpaired T-test. (c–e) Primary hepatocytes were isolated from 10 to 15 weeks old WT and NRK1KO male mice. Protein (c) and mRNA (d) levels of NRK1 and other enzymes involved in NAD+ metabolism. (e) NAD+ measurement after 6 h treatment with 0.5 mM NR, 0.5 mM NMN, 5 mM NAM, 0.5 mM NA or vehicle control. Results shown are mean±s.e.m., *P<0.05 versus WT by two-sided unpaired T-test. (n=3).
Figure 5 NRK1 is essential for NR and NMN to enhance NAD+ synthesis in hepatic cells. (a,b) AML12 cells were transfected with NRK1 siRNA. (a) Protein and mRNA levels of NRK1 and other NAD+-related enzymes. (b) NAD+ measurement after 6 h 0.5 mM NR treatment. *P<0.05 versus ctrl by two-sided unpaired T-test. (c–e) Primary hepatocytes were isolated from 10 to 15 weeks old WT and NRK1KO male mice. Protein (c) and mRNA (d) levels of NRK1 and other enzymes involved in NAD+ metabolism. (e) NAD+ measurement after 6 h treatment with 0.5 mM NR, 0.5 mM NMN, 5 mM NAM, 0.5 mM NA or vehicle control. Results shown are mean±s.e.m., *P<0.05 versus WT by two-sided unpaired T-test. (n=3).CC BY · PubMed Central
Figure 6 Extracellular conversion of NMN to NR by hepatocytes. (a) Primary hepatocytes were isolated from 10 to 15 weeks old WT mice. Cells were treated with 2 μM FK866 and ±2 mM CMP for 1 h. Then, 0.5 mM NR or NMN was added and NAD+ was measured after 2 h. (b,c) WT (b) and NRK1KO (c) hepatocytes were treated with [2H]-[13C]-double labelled NR or NMN. Intracellular enrichment of labelled compounds. Results shown are mean±s.e.m., **P<0.01 versus ctrl by two-sided unpaired T-test (n=3).
Figure 6 Extracellular conversion of NMN to NR by hepatocytes. (a) Primary hepatocytes were isolated from 10 to 15 weeks old WT mice. Cells were treated with 2 μM FK866 and ±2 mM CMP for 1 h. Then, 0.5 mM NR or NMN was added and NAD+ was measured after 2 h. (b,c) WT (b) and NRK1KO (c) hepatocytes were treated with [2H]-[13C]-double labelled NR or NMN. Intracellular enrichment of labelled compounds. Results shown are mean±s.e.m., **P<0.01 versus ctrl by two-sided unpaired T-test (n=3).CC BY · PubMed Central
Figure 7 NAD+ in vivo metabolism in NRK1KO mice. Five to six weeks old WT and NRK1KO male mice were IP injected with 500 mg kg−1 of the indicated compounds. Then, liver, kidney, brown adipose (BAT) and skeletal muscle samples were collected after 1 h, n=5 per group. NAD+ measurement in liver (a), total kidney extracts (c), BAT (e) and muscle (g) tissue. Percentage increase above basal NAD+ level in liver (b), kidney (d), BAT (f) and muscle (h) tissue upon treatments. Results shown are mean±s.e.m., *P<0.05, **P<0.01, ***P<0.001 versus WT by two-sided unpaired T-test (n=5).
Figure 7 NAD+ in vivo metabolism in NRK1KO mice. Five to six weeks old WT and NRK1KO male mice were IP injected with 500 mg kg−1 of the indicated compounds. Then, liver, kidney, brown adipose (BAT) and skeletal muscle samples were collected after 1 h, n=5 per group. NAD+ measurement in liver (a), total kidney extracts (c), BAT (e) and muscle (g) tissue. Percentage increase above basal NAD+ level in liver (b), kidney (d), BAT (f) and muscle (h) tissue upon treatments. Results shown are mean±s.e.m., *P<0.05, **P<0.01, ***P<0.001 versus WT by two-sided unpaired T-test (n=5).CC BY · PubMed Central
Figure 8 Intraperitoneal injected NR and NMN partially degrades to NAM. (a–d) Five to six weeks old WT and NRK1KO male mice were IP injected with 50 mg kg−1 of indicated compound and blood liver samples were collected after 1 h, n=4 per group. Then, NAM level in liver (a) and plasma (b) were measured, as well as NR level in liver (c) and plasma (d) of these animals. (e–g) NR and NMN stability in isolated murine plasma. Plasma samples were isolated from NRK1KO mice. 0.5 mM NR or NMN was incubated with plasma at 37 °C for 60 min. NR (e), NMN (f) and NAM (g) level was measured in samples by LC-QqQ MS. Results shown are mean±s.e.m., *P<0.05 versus WT; #P<0.05 versus vehicle by one-way ANOVA followed by Bonferroni's post-hoc test (n=3).
Figure 8 Intraperitoneal injected NR and NMN partially degrades to NAM. (a–d) Five to six weeks old WT and NRK1KO male mice were IP injected with 50 mg kg−1 of indicated compound and blood liver samples were collected after 1 h, n=4 per group. Then, NAM level in liver (a) and plasma (b) were measured, as well as NR level in liver (c) and plasma (d) of these animals. (e–g) NR and NMN stability in isolated murine plasma. Plasma samples were isolated from NRK1KO mice. 0.5 mM NR or NMN was incubated with plasma at 37 °C for 60 min. NR (e), NMN (f) and NAM (g) level was measured in samples by LC-QqQ MS. Results shown are mean±s.e.m., *P<0.05 versus WT; #P<0.05 versus vehicle by one-way ANOVA followed by Bonferroni's post-hoc test (n=3).CC BY · PubMed Central

Verification

Claims the paper makes

12 Valid · 1 Not valid · 12 Not checked · 97 Own results and interpretations

50 more claims

Create a free account to see all 122 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 25
  • It may state two separate claims as one. 49
  • Borderline: one of the tests for a substantial claim is unclear. 1
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Cited by

See all 378

Metadata

Authors
Ratajczak, J., Joffraud, M., Trammell, S. A. J., Ras, R., Canela, N., Boutant, M., Kulkarni, S. S., Rodrigues, M., Redpath, P., Migaud, M. E., Auwerx, J., Yanes, O., Brenner, C., & Cantó, C.
Affiliations
  • École Polytechnique Fédérale de Lausanne (CH)
  • University of Iowa (US)
  • Centre for Omic Sciences (ES)
  • Queen's University Belfast (GB)
Corresponding author
  • Brenner, Charles
  • Cantó, Carles
Venue
Nature Communications
Published
2016-10-11
Volume
7
Issue
1
Pages
13103-13103
ISSN
2041-1723 (ISSN-L)
OpenAlex
W2531686927
Cited by
378
References
46
Citations by year
2026: 34 · 2025: 35 · 2024: 48 · 2023: 46 · 2022: 38 · 2021: 40 · 2020: 31 · 2019: 43 · 2018: 28 · 2017: 31 · 2016: 2
FWCI
19.91
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, other-oa)
  • Research Portal (Queen's University Belfast) (publishedVersion, cc-by)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion)
  • Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion, cc-by-nc-nd)
Funders
  • Roy J. Carver Charitable Trust
  • École Polytechnique Fédérale de Lausanne
  • National Institutes of Health
  • Directorate for Biological Sciences
  • Biotechnology and Biological Sciences Research Council (BB/N001842/1)
  • National Institute on Alcohol Abuse and Alcoholism (R21AA022371)
  • National Heart, Lung, and Blood Institute (R01HL108379)
  • National Institute of General Medical Sciences (T32GM008629)
Topics
  • Health Sciences › Medicine › Geriatrics and Gerontology › Sirtuins and Resveratrol in Medicine
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Biochemical and Molecular Research
  • Health Sciences › Nursing › Nutrition and Dietetics › Folate and B Vitamins Research
Keywords
nicotinamide mononucleotide, nicotinamide riboside, NAD+ synthesis, NAD+ precursors, sirtuins, poly(ADP-ribose) polymerase, NAD+ supplementation
MeSH terms
Animals, Humans, Injections, Intraperitoneal, Mammals, NAD, Niacinamide, Nicotinamide Mononucleotide, Pyridinium Compounds, Phosphotransferases (Alcohol Group Acceptor), Mice, Knockout, Hepatocytes, Hep G2 Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-09, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-09 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.